Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
MCM2 CRISPR/Cas9 KO Plasmid (h): sc-400959
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- MCM2 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the MCM2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: MCM2 Antibody (E-8): sc-373702
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MCM2 CRISPR/Cas9 KO Plasmid (h) | sc-400959 | 20 µg | $397.00 |
Overview
MCM2 (minichromosome maintenance complex component 2) is an essential AAA+ ATPase within the MCM2–7 helicase that licenses replication origins and drives DNA unwinding during S phase. By coordinating origin firing, replication fork progression, and checkpoint responses, MCM2 helps maintain genome stability and supports orderly cell-cycle transit through the G1/S boundary. Dysregulated MCM2 expression or replication licensing can contribute to replication stress, DNA damage signaling, and chromosomal instability, processes frequently examined in cancer biology and proliferative disorders. As a core replisome factor, MCM2 is also studied in contexts of ATR/CHK1-dependent replication stress pathways and responses to genotoxic perturbation.
MCM2 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the MCM2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the MCM2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the MCM2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish MCM2 protein expression.
This CRISPR knockout system enables efficient generation of MCM2-deficient cell models for investigation of MCM2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting MCM2 exon(s) critical for MCM2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple MCM2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by MCM2 CRISPR/Cas9 KO Plasmid (h) and MCM2 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the MCM2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by MCM2 HDR Plasmid (h) and MCM2 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by MCM2 homology arms to support homology-directed repair at defined MCM2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.